Dividend Channel
Market News Video Dividend Detective The Warren Buffetts Next Door Stock message boards
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

Analysts Predict 11% Gains Ahead For JKJ
Tuesday, February 20, 8:31 AM ET, by Market News Video Staff

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, ...

Horizon Pharma Moves Up In Market Cap Rank, Passing Patterson Companies
Friday, March 9, 4:47 PM ET, by Market News Video Staff

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Horizon ...

Analysts Forecast 12% Upside For The Holdings of TUSA
Friday, March 23, 10:28 AM ET, by Market News Video Staff

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, ...

Commit To Buy Horizon Pharma At $10, Earn 11% Using Options
Friday, April 6, 12:02 PM ET, by Market News Video Staff

Investors considering a purchase of Horizon Pharma plc (HZNP) shares, but cautious about paying the ...

Add Up The Pieces: JKJ Could Be Worth $192
Monday, April 23, 9:24 AM ET, by Market News Video Staff

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, ...

HZNP Crosses Above Average Analyst Target

By Dividend Channel Staff, Friday, August 10, 7:56 AM ET
Play Video: The Importance of ETFs

If the video does not load after a few moments, Upgrade to the Latest Flash Player.

In recent trading, shares of Horizon Pharma plc (NASDAQ:HZNP) have crossed above the average analyst 12-month target price of $20.50, changing hands for $20.91/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher if things are looking up for the company, perhaps it is time for that target price to be raised.

There are 8 different analyst targets contributing to that average for Horizon Pharma plc, but the average is just that a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $16.00. And then on the other side of the spectrum one analyst has a target as high as $24.00. The standard deviation is $2.927.

But the whole reason to look at the average HZNP price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with HZNP crossing above that average target price of $20.50/share, investors in HZNP have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $20.50 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover Horizon Pharma plc:

Recent HZNP Analyst Ratings Breakdown
Current 1 Month Ago 2 Month Ago 3 Month Ago
Strong buy ratings: 6 6 6 6
Buy ratings: 0 0 0 0
Hold ratings: 2 1 0 1
Sell ratings: 0 0 0 0
Strong sell ratings: 0 0 0 0
Average rating: 1.5 1.29 1.0 1.29

The average rating presented in the last row of the above table above is from 1 to 5 where 1 is Strong Buy and 5 is Strong Sell. This article used data provided by Zacks Investment Research via Quandl.com. Get the latest Zacks research report on HZNP FREE.

This Article's Word Cloud:   Analyst   Average   Below   Breakdown   Current   ETFs   FREE   HZNP   Hold   Horizon   Investment   Month   Most   Pharma   Quandl   Ratings   Recent   Research   Sell   Start   Strong   Targets   There   This   Upside   When   With   Zacks   above   analyst   analysts   average   company   have   higher   just   looking   price   rating   ratings   share   stock   table   target   targets   that   time   valuation   where   with

HZNP Crosses Above Average Analyst Target | www.DividendChannel.com | Copyright © 2010 - 2019, All Rights Reserved

Nothing in Dividend Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and dividend videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact Dividend Channel; Meet Our Editorial Staff.